Prophylaxis and therapy of infections in neutropenic patients

Current Opinion in Infectious Diseases

Volumn 9, Issue 4, 1996, Pages 218-222

  Philpott Howard, John ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; COLIFORM BACTERIUM; ENTEROCOCCUS; HUMAN; MYCOSIS; NEUTROPENIA; REVIEW; STREPTOCOCCUS INFECTION; SUPERINFECTION;

EID: 0029830152     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199608000-00002     Document Type: Review

References (39)

1. Wenzel R: The economics of nosocomial infections. J Hosp Infect 1995, 31:79-87.
2. Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik • SD: Long-term survival following bacteremia or fungemie. JAMA, 1995, 274:807-812. This study examined long-term survival after bacteraemia or fungaemia in a wide range of patients. Neutropenic patients had a median survival of 2.4 months compared with 36 months in non-neutropenic patients. A particularly high mortality was common in the second month after infection.
3. Hughes WT, Flynn PM, Willams BG: Nosocomial Infection in patients • with neoplastic diseases. In Hospital epidemiology and infection control. Edited by Mayhall CG. Baltimore: Williams and Wilkins; 1996:618-631. This chapter is a useful review of nosocomial infection rates and preventive measures. It is part of a comprehensive textbook covenng a wide range of infection control issues affecting compromised and other patients.
4. Rubie H, Juricic M, Claeyssens S, Krimou A, Lemozy J, Izard P, Guitard J, Ane M, Prere MF, Fedacou F et al.: Morbidity using subcutaneous ports and efficacy of vancomycin flushing in cancer. Arch Dis Child 1995, 72:325-329.
5. Vassilomanolakis M, Plataniotis G, Koumakis G, Hajichnstou H, Skouteri H, Dova H, Efremidis AP: Central venous catheter-related infections after bone marrow transplantation in patients with malignancies: a prospective study with short-course vancomycin prophylaxis. Bone Marrow Transplant 1995, 15:77-80.
6. Barker GJ, Call SK, Garnis AS: Oral care with vancomycin paste for reduction in incidence of alpha-hemolytic streptococcal sepsis. J Pediatr Hematol Oncol 1995, 17:151-155.
7. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP: Vancomycin-reslstant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995, 20:1126-1133.
8. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, Bland LA, Jarvis WR: Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995, 172:993-1000.
9. Carratalá J, Fernández-Sevilla A, Tubau F, Callis M, Gudiol F: • Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Intect Dis 1995, 20:557-560. Since 1987 these workers have used norfloxacin prophylaxis and now demonstrate that 13 out of 35 (37%) strains of E. coli from bacteraemias were resistant. There was no clustering of cases to suggest cross-infection.
10. •] which usefully discusses the issue of restriction of quinolones and relates their use in hospitals to that in the community. Quinolone prophylaxis is effective and therefore should only be restricted if there is a significant problem of quinolone resistance in the community.
11. Crumplin GC: Quinolone/ureidopenicillin cross-resistance in Gramnegative bacteria. Lancet 1987, 2:1519-1520.
12. Philpott-Howard J: Infections in neutropenic patients. Curr Opin Infect Dis 1995, 8:234-240.
13. Carratalá J, Alcaide F, Fernández-Sevilla A, Corbella X, Linares J, Gudiol F: Bacteraemia due to viridans streptococci that are highly resistant to penicllin: increase among neutropenic patients with cancer. Clin Infect Dis 1995, 20:1169-1173.
14. Beighton D, Carr AD, Oppenheim BA: Identification of viridans streptococci associated with bacteraemia in neutropenic cancer patients. J Med Microbiol 1994, 40:202-204.
15. Homer KA, Kelley S, Hawkes J, Beighton D, Grootveld MC: Metabolism of glycoprotein-derived sialic acid and N-acetylglucosamine by Streptococcus oralis. Microbiology 1996, 142:1221-1230.
16. Aquino VM, Smyrl CB, Hagg R, McHard KM, Prestridge L, Sandier ES: • Enterai nutritional support by gastrostomy tube in children with cancer. J Pediatr 1995, 127:58-62. A retrospective study which suggests that improved nutrition (through a gastrostomy tube) reduced nosocomial infections when compared with total parenteral nutrition, from 1.58 infections/1000 days compared with 5.0/ 1000 days for total parenteral nutrition.
17. Richard P. Delvalle GA, Moreau P, Milpied N, Felice MP, Daeschler T, Harousseau JL, Richet H: Viridans streptococcal bacteraemia in patients with neutropenia. Lancet 1995, 345:1607-1609.
18. Donnelly JP, Dompeling EC, Meis JF, de Pauw BE: Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor than antibacterial prophylaxis. Clin Infect Dis 1995, 20:469-470.
19. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, •• Langenaeken J, Paesmans M, Viscoli C, Glauser MP: Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995, 39:445-452. The major finding of this study was the higher rate of success without modification in the piperacillin-tazobactam arm (61% versus 54%), with a shorter time to defervescence and a longer time to clinical success. There was no significant difference in outcome for Gram-positive bacteraemias but there was for bacteraemias overall, favouring piperacillin-tazobactam. The mortality in each group was the same (8%).
20. Bow EJ, Loewen R, Vaughan D: Reduced requirement for antibiotic therapy targeting Gram-negative organisms In febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995, 20:907-912.
21. Velasco E, Costa MA, Martins CA, Nucci M: Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Am J Clin Oncol 1995, 18:429-435.
22. Chandrasekar PH, Weinmann A, Shearer C and the Bone Marrow Transplant Team: Autopsy-identified infections among bone marrow transplant recipients: a clinico-pathologic study of 56 patients. Bone Marrow Transplant 1995, 16:675-681.
23. Garaventa A, Rondelli R, Castagnola E, Locatelli F, Dallorso S, Porta F, •• Uderzo C, Rossetti F, Miniero R, Andolina M et al. for the Italian Association of Pediatric Hematology-Oncology BMT group: Fatal pneumopathy in children after bone marrow transplantation - report from the Italian Registry. Bone Marrow Transplant 1995, 16:669-674. In this very large descriptive study of 1134 children undergoing a variety of BMT procedures, infection was responsible for 32 deaths. Apart from the graft type, only lack of PCP prophylaxis was significantly associated with fatal lung disease. Trimethoprim-sulphamethoxazole three times a week also protected against other infections (cumulative incidence of 8.1% fatal pneumopathy for PCP prophylaxis versus 16.2% for no prophylaxis; relative risk 2.0).
24. Pannuti C, Gingnch R, Pfaller MA, Kao C, Wenzel RP: Nosocomial pneumonia in patients having bone marrow transplant Attributable mortality and risk factors. Cancer 1992, 69:2653-2662.
25. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS: A metaanalysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Ann Intern Med 1996, 156:177-188.
26. Slavm MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman •• AR, Meyers JD, Bowden RA: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation. A prospective, randomized, double blind study. J Infect Dis 1995, 171:1545-1552. Fluconazole was administered until day 75 after BMT and, as expected, there was a decrease in systemic candidiasis from 18% to 7%. There was also a decrease in overall mortality at day 110, and more patients receiving fluconazole developed graft-versus-host disease but the risk of death from graft-versus-host disease was lower in the fluconazole arm. There were no infections with C. krusei and no increase in infections caused by C. glabrata.
27. Flynn PM, Cunningham CK, Kerkering T, Sanjorge AR, Peters VB, Pitel • PA, Harris J, Gilbert G, Castagnaro L, Robinson P and the Multicenter Fluconazole Study Group: Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. J Pediatr 1995, 127:322-328. A 91% cure rate was achieved for patients receiving fluconazole compared with 51% for nystatin. C. krusei was seen in only three patients. The study confirms that topical nystatin is a sub-optimal therapy for candidiasis in neutropenic patients.
28. Schaffner A, Schaffner M: Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995, 172:1035-1041.
29. de Pauw BE, Raemaekers JM, Donnelly JP, Kullberg BJ, Meis JF: An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann Hematol 1995, 70:83-87.
30. Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA: Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995, 76:2357-2362.
31. Schaffner A, Frick PG: The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985, 151:902-910.
32. Sugar AM, Hitchcock CA, Troke PF, Picard M: Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995, 39:598-601.
33. Walsh TJ, Peter J, McGough DA, Fothergill AW, Rinaldi MG, Pizzo PA: Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother 1995, 39:1361-1364.
34. Walsh TJ, Garrett K, Feurerstein E, Girton M, Allende M, Bacher J, Francesconi A, Schaufele R, Pizzo PA: Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother 1995, 39:1065-1069.
35. McWhinney PH, Kibbler CC, Hamon MD, Smith OP, Gandhi L, Berger LA, Hoffbrand AV, Prentice HG: Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993, 17:397-404.
36. Robinson LA, Reed EC, Galbraith TA, Alonso A, Moulton AL, Fleming WH: Pulmonary resection for invasive Aspergillus infections in immunocompromised patients. J Thorac Cardiovasc Surg 1995, 109:1182-1196.
37. Ljungman P, Cordonnier C, Debock R, Einsele H, Engelhard D, Grundy • J, Link H, Locasciulli A, Prentice G, Reusser P, Ribaud P: Immunisations after BMT: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1995, 15:455-460. This study demonstrates the diversity of practice in BMT immunoprophylaxis in Europe but provides a useful summary of recommendations.
38. Barnes RA: Immunotherapy and immunoprophylaxis in bone marrow transplantation. J Hosp Infect 1995 30(suppl 30):223-231.
39. Roilides E, Sein T, Holmes A, Chanock S, Blake C, Pizzo PA, Walsh TJ: Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis 1995, 172:1028-1034.